Top Markets
Coin of the day
AcelRx Pharmaceuticals, Inc. AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc.

ACRX
Classement en actions #31911
AcelRx Pharmaceuticals, Inc. is a specialized biopharmaceutical firm primarily... AcelRx Pharmaceuticals, Inc. is a specialized biopharmaceutical firm primarily dedicated to advancing and bringing to market medical solutions for managing acute pain. The company's key commercial products include DSUVIA and DZUVEO, which are 30 microgram sufentanil tablets administered under the tongue, intended for treating significant short-term pain. AcelRx also develops ZALVISO, a pre-programmed, patient-managed analgesia system that enables hospital patients experiencing moderate-to-severe acute pain to self-administer sufentanil sublingual tablets for their pain relief. In its development pipeline, AcelRx is progressing ARX-02, which is currently in Phase 2 clinical trials, targeting sudden, intense cancer-related pain in individuals who are tolerant to opioid medications. Another candidate, 4ARX-03, is being investigated for its utility in providing mild sedation and pain relief during various medical procedures that might cause discomfort. Beyond acute pain, AcelRx's investigational portfolio features Niyad, a regional anticoagulant designed for use in external blood circulation systems. Furthermore, LTX-608, a nafamostat formulation for direct intravenous infusion, is being explored as an experimental treatment for a range of conditions, including COVID, severe lung injury (acute respiratory distress syndrome), widespread blood clotting (disseminated intravascular coagulation), and acute pancreatitis. The company was founded in 2005 and initially operated under the name SuRx, Inc., before officially rebranding as AcelRx Pharmaceuticals, Inc. in August 2006. It is headquartered in Hayward, California.
Prix de l'action
$0.922
Dernière synchronisation: 2024-02-05
Capitalisation boursière
$11.68M
Changement (1 jour)
-1.91%
Changement (1 an)
0.00%
Pays
US
Échange AcelRx Pharmaceuticals, Inc. (ACRX)

Catégorie

EPS pour AcelRx Pharmaceuticals, Inc. (ACRX)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de AcelRx Pharmaceuticals, Inc., l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de AcelRx Pharmaceuticals, Inc. de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires